- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Intermediate Host.
Displaying page 1 of 2.
EudraCT Number: 2012-004118-33 | Sponsor Protocol Number: trapiantoover66 | Start Date*: 2013-06-17 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: High-dose cyclophosphamide role in the prophylaxis of GVHD in elderly patients (66-70 years) with acute leukemia or myelodysplasia high-risk, submitted to allogenic transplant of peripheral hematop... | |||||||||||||
Medical condition: Elderly patients (66-70 years) with acute leukemia or high-risk MDS who, underwent allogenic transplant of peripheral hematopoietic progenitors after reduced-intensity conditioning. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000329-29 | Sponsor Protocol Number: CSL964_2001 | Start Date*: 2019-05-31 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versus-host disease in patients ... | |||||||||||||
Medical condition: Graft versus host disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002864-36 | Sponsor Protocol Number: PKRPC001 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:Priothera S.A.S. | |||||||||||||
Full Title: A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing alloge... | |||||||||||||
Medical condition: Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001534-42 | Sponsor Protocol Number: TrRaMM4Gy | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies | |||||||||||||
Medical condition: Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched fa... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004225-24 | Sponsor Protocol Number: PCI-32765CAN3001 | Start Date*: 2013-01-15 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | ||||||||||||||||||||||||||||
Medical condition: chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) PL (Trial now transitioned) ES (Ongoing) SE (Ongoing) BE (Trial now transitioned) IE (Completed) PT (Ongoing) HU (Ongoing) NL (Ongoing) GR (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004010-34 | Sponsor Protocol Number: ClaTBI/2019 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach | |||||||||||||
Full Title: Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukem... | |||||||||||||
Medical condition: Accute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004672-21 | Sponsor Protocol Number: CR-AIR-009 | Start Date*: 2017-06-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Kiadis Pharma Netherlands B.V. | |||||||||||||||||||||||||||||||||
Full Title: A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation de... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with a hematologic malignancy (AML, ALL, or MDS) who are eligible for a haploidentical HSCT | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Completed) PT (Completed) NL (Prematurely Ended) HR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002331-41 | Sponsor Protocol Number: HaploMUDStudy | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:University Medical Center Hamburg - Eppendorf | |||||||||||||
Full Title: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized Prospective European Trial | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000853-17 | Sponsor Protocol Number: DKMS-21-01 | Start Date*: 2021-11-11 |
Sponsor Name:DKMS Group gGmbH | ||
Full Title: Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG | ||
Medical condition: AML, t-MN, MDS, MDS/MPN, CMML-1/CMML-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005210-28 | Sponsor Protocol Number: MMM02Study | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study) | |||||||||||||
Medical condition: primary myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005477-54 | Sponsor Protocol Number: TrRaMM | Start Date*: 2007-12-03 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO | |||||||||||||
Full Title: Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haem... | |||||||||||||
Medical condition: neoplastic and haematologic patologies | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002821-20 | Sponsor Protocol Number: CR-AIR-008 | Start Date*: 2015-10-01 | |||||||||||||||||||||||||||||||
Sponsor Name:Kiadis Pharma Netherlands B.V. | |||||||||||||||||||||||||||||||||
Full Title: An exploratory, open-label, multicenter study to evaluate the safety and efficacy of a two-dose regimen of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreacti... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with a hematologic malignancy (AML, ALL, or MDS) who are eligible for a haploidentical HSCT | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) PT (Completed) HR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004461-41 | Sponsor Protocol Number: CR-AIR-007 | Start Date*: 2013-06-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Kiadis Pharma Netherlands B.V. | |||||||||||||||||||||||||||||||||
Full Title: An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignan... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with a hematologic malignancy (AML, ALL, or MDS) who are eligible for a haploidentical HSCT | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005010-19 | Sponsor Protocol Number: MPD-RC114 | Start Date*: 2014-11-25 | |||||||||||
Sponsor Name:Consorzio Mario Negri Sud | |||||||||||||
Full Title: Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis | |||||||||||||
Medical condition: Primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000602-18 | Sponsor Protocol Number: BMT-CTN#1301 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:National Heart, Lung, and Blood Institute (NHLBI) | |||||||||||||
Full Title: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease | |||||||||||||
Medical condition: Acute Leukemia in morphologic complete remission Myelodisplasia with less than 5% blasts in the marrow and no circulating blasts | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003181-32 | Sponsor Protocol Number: CIMNK1001 | Start Date*: 2011-10-14 | ||||||||||||||||
Sponsor Name:Karolinska University Hospital | ||||||||||||||||||
Full Title: In vivo expansion and efficacy of adoptive natural killer cell-based immunotherapy for high-risk myeloid diseases | ||||||||||||||||||
Medical condition: acute myeloid leukemia and myelodysplastic syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000827-94 | Sponsor Protocol Number: U-DANCE-anti-AML | Start Date*: 2016-09-08 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial | ||||||||||||||||||
Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Not Authorised) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017376-25 | Sponsor Protocol Number: MEK111759 | Start Date*: 2011-03-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Ref... | |||||||||||||
Medical condition: Relapsed or refractory leukemias | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005173-20 | Sponsor Protocol Number: MEDI4736-DLBCL-001 | Start Date*: 2016-12-21 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or... | |||||||||||||
Medical condition: Previously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DK (Prematurely Ended) EE (Temporarily Halted) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005889-38 | Sponsor Protocol Number: UCL/10/0411 | Start Date*: 2012-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University College London | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Acute myeloid leukaemia Myelodysplastic syndromes Therapy related AML or MDS Philadelphia positive Chronic Myeloid Leukaemia Acute lymphoblastic leukaemia Non-Hodgkin's lymphoma (follicular lymphom... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.